In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

U.S. stocks were on track to open higher on Wednesday after in-line consumer price inflation data kept the Federal Reserve on ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Thomas also held leadership posts with Novartis, Bristol-Myers Squibb, Beigene, GSK and Amgen. Thomas received a bachelor's ...

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares closed yesterday at $298.84.

Devarakonda covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Incyte. In addition to Truist Financial, Amgen also received a Hold from Barclays’s Carter Gould in a ...